about
Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivatorHoney flavonoids inhibit hOATP2B1 and hOATP1A2 transporters and hOATP-mediated rosuvastatin cell uptake in vitro.Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis.Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.Modulatory effects of quercetin and rutin on the activity, expression and inducibility of CYP1A1 in intestinal HCT-8 cells.Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay.Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab.Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.A comparison of in vitro methods for determining the membrane receptor expression in cell lines.Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression.Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity.The in vivo disposition and in vitro transmembrane transport of two model radiometabolites of DOTA-conjugated receptor-specific peptides labelled with (177) Lu.Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug InteractionsBiotransformation of anthelmintics and the activity of drug-metabolizing enzymes in the tapeworm Moniezia expansa.Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.A resurrection of 7-MEOTA: a comparison with tacrine.Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.How to address the sample preparation of hydrophilic compounds: Determination of entecavir in plasma and plasma ultrafiltrate with novel extraction sorbents.Stereoselective pharmacokinetics and metabolism of flobufen in guinea pigs.Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity.Novel derivatives of nitro-substituted salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation.In vitro evaluation of concentration, labeling effectiveness and stability for 131 I-labeled radioimmunoassay ligand using real-time detection technology.Iron reduction potentiates hydroxyl radical formation only in flavonols.Corrigendum to "Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity" [Bioorg. Med. Chem. 25 (2017) 1524-1532].Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.The involvement of selected membrane transport mechanisms in the cellular uptake of (177)Lu-labeled bombesin, somatostatin and gastrin analogues.Antibacterial Activity of Salicylanilide 4-(Trifluoromethyl)-benzoatesHighly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography–ultra-high-performance liquid chromatography–tandem mass spectrometrySynthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analoguesSynthesis and in vitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2′-hydroxybenzanilides, their thioxo analogues and benzoxazoles3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial EvaluationDesign, synthesis and anti-mycobacterial evaluation of some new N-phenylpyrazine-2-carboxamidesAntimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffoldStudy of the biotransformation of a potential benzo[c]fluorene antineoplastic using high-performance liquid chromatography with high-speed-scanning ultraviolet detection
P50
Q34298854-46E70973-4C22-4C05-AECA-3A858220D5CBQ36830111-5AB7AAAE-E31A-4195-B182-9166BEB3BC58Q38660774-AEA4A372-C8D8-4090-944C-309274EF7D66Q38857408-E219218E-5C05-4800-9DC3-03F38F0A90EAQ38859468-5AC0EF57-E52E-4F8B-A696-CA97E4C71780Q38988829-0C72EEC9-CB52-4660-91B3-E9E923F47E4CQ39125579-78A104DD-9DF5-4621-94D6-58EB89A91F35Q39149961-6A7BDFE6-BF38-4861-8856-D3967E5BBABFQ39171946-154AF373-7F65-45B3-BEE8-8E91D01AE0B4Q39182026-25512463-7C01-4C8E-BC5C-FA54C33D61BEQ39185059-B5E45066-AE4F-493B-AE22-AD7F7D3D471BQ39365287-C71FFF16-6FA9-4F9B-AC60-EADDD6F34A07Q40052938-4E6CD2DC-09B4-4633-84BF-0FF5736CC0F0Q40314053-2B3352A4-40AD-4A03-B5E4-0BDB136B7A45Q40364919-C62BCDB0-D5A7-49F2-A39A-B8500FB5015BQ40829113-8B9FD6AD-F5BC-4FB1-9B7E-00D6B5F16605Q41675505-64E51926-CFA9-467A-B162-11537E577B68Q42707770-B09BE761-227D-4E2D-829C-6E241AE23E09Q43853083-86123DC9-8ADC-4236-83DD-837231DC174DQ44096275-E5833B45-1D98-4E4D-9B89-E795363D3553Q44311310-CDBD9327-31D6-4415-992F-9DFBA8E60832Q44552593-EF3314B4-9CAA-40FB-A979-F1D390778C53Q44794920-421BDB4D-A8F0-41E6-801B-9A4B5FEAA012Q46163990-4C7BFEBF-BC23-4E29-B8B8-7C1F286C7C8AQ46304589-7E46F4B8-CE05-4A21-A798-C0BDB784BD05Q46645003-F14B4271-E6D6-4C19-8E67-8BA1A9B1FF45Q47957586-1C9B8E0F-EA98-44E7-96E9-49A5B123C267Q51013022-7BC15779-1B7E-4AA3-A022-84C8C72E24FCQ51550456-BE116F6D-02C6-4859-B3DB-A80287FFC500Q53442127-17243C02-36AE-48E1-99E6-B85B0E1EBA73Q53752600-6999E08E-471B-44A6-985C-2AA1BCDACC6DQ53771666-67692A5D-C4A1-428A-879D-0C63A39DF6C6Q58851373-8F0E14B3-85ED-4B72-B981-F243C667CFC5Q58851396-C787449A-EDA1-4DA3-8AE2-ECE7324F3AEBQ58930010-850BBBDF-0D4C-4FC1-A564-992D6859914BQ58930015-941423D4-28A5-4AB1-8BAB-4A86341EA4D1Q59054226-FCDA2A4F-E730-4AF0-B05A-4CD74BEC9886Q59054275-3DA191B2-4B26-4CDD-81F9-620B97DF70A4Q61877345-EA31362D-0A08-4785-A226-A527E1A28A24Q71515548-148CA44E-C937-40DA-9BA6-788C58724555
P50
description
farmakolog, toxikolog
@cs
researcher ORCID ID = 0000-0003-0643-3686
@en
wetenschapper
@nl
name
František Trejtnar
@ast
František Trejtnar
@cs
František Trejtnar
@en
František Trejtnar
@es
František Trejtnar
@nl
type
label
František Trejtnar
@ast
František Trejtnar
@cs
František Trejtnar
@en
František Trejtnar
@es
František Trejtnar
@nl
prefLabel
František Trejtnar
@ast
František Trejtnar
@cs
František Trejtnar
@en
František Trejtnar
@es
František Trejtnar
@nl
P106
P214
P1153
6603878630
P214
P31
P496
0000-0003-0643-3686
P569
1959-12-17T00:00:00Z